Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors

被引:366
作者
Yu, P [1 ]
Lee, Y
Liu, WH
Krausz, T
Chong, A
Schreiber, H
Fu, YX
机构
[1] Univ Chicago, Committee Immunol, Chicago, IL 60637 USA
[2] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA
[3] Univ Chicago, Dept Surg, Chicago, IL 60637 USA
关键词
D O I
10.1084/jem.20041684
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Tumor environment can be critical for preventing the immunological destruction of antigenic tumors. We have observed a selective accumulation of CD4(+)CD25(+) T cells inside tumors. In a murine fibrosarcoma L-d-expressing Ag104, these cells made up the majority of tumor-infiltrating lymphocytes at the late stage of tumor progression, and their depletion during the effector phase, rather than priming phase, successfully enhanced antitumor immunity. We show here that CD4(+)CD25(+) T cells suppressed the proliferation and interferon-gamma production of CD8(+) T cells in vivo at the local tumor site. Blockade of the effects of IL-10 and TGF-beta partially reversed the suppression imposed by the CD4(+) cells. Furthermore, local depletion of CD4(+) cells inside the tumor resulted in a change of cytokine milieu and led to the eradication of well-established highly aggressive tumors and the development of long-term antitumor memory. Therefore, CD4(+)CD25(+) T cells maintained an environment in the tumor that concealed the immunogenicity of tumor cells to permit progressive growth of antigenic tumors. Our study illustrates that the suppression of antitumor immunity by regulatory T cells occurs predominantly at the tumor site, and that local reversal of suppression, even at a late stage of tumor development, can be an effective treatment for well-established cancers.
引用
收藏
页码:779 / 791
页数:13
相关论文
共 75 条
[2]   Regulatory T cells under scrutiny [J].
Bach, JF .
NATURE REVIEWS IMMUNOLOGY, 2003, 3 (03) :189-198
[3]   Point mutation in essential genes with loss or mutation of the second allele: Relevance to the retention of tumor-specific antigens [J].
Beck-Engeser, GB ;
Monach, PA ;
Mumberg, D ;
Yang, F ;
Wanderling, S ;
Schreiber, K ;
Espinosa, R ;
Le Beau, MM ;
Meredith, SC ;
Schreiber, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 194 (03) :285-299
[4]   CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity [J].
Belkaid, Y ;
Piccirillo, CA ;
Mendez, S ;
Shevach, EM ;
Sacks, DL .
NATURE, 2002, 420 (6915) :502-507
[5]  
BERENDT MJ, 1980, J EXP MED, V151, P69, DOI 10.1084/jem.151.1.69
[6]   Human tumor antigens recognized by T lymphocytes [J].
Boon, T ;
vanderBruggen, P .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (03) :725-729
[8]   CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-γ-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination [J].
Casares, N ;
Arribillaga, L ;
Sarobe, P ;
Dotor, J ;
de Cerio, ALD ;
Melero, I ;
Prieto, J ;
Borrás-Cuesta, F ;
Lasarte, JJ .
JOURNAL OF IMMUNOLOGY, 2003, 171 (11) :5931-5939
[9]   MODEL PREDICTING SURVIVAL IN STAGE-I MELANOMA BASED ON TUMOR PROGRESSION [J].
CLARK, WH ;
ELDER, DE ;
GUERRY, D ;
BRAITMAN, LE ;
TROCK, BJ ;
SCHULTZ, D ;
SYNNESTVEDT, M ;
HALPERN, AC .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (24) :1893-1904
[10]  
Clemente CG, 1996, CANCER, V77, P1303, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO